Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors.

被引：1
|
作者：
Garcaa-Donas, Jesas
Roldan, Jose Maria
Lainez, Nuria
Castellano, Daniel E.
Gonzalez, Emilio Esteban
Climent, Miguel A.
Puente, Javier
Francisco Rodriguez-Moreno, Juan
Alonso Gordoa, Teresa
Gonzalez del Alba, Aranzazu
Angel Arranz, Jose
Santos, Maria
Hernando Polo, Susana
Domenech, Montserrat
Rodriguez, Laura
Herrador, Alejandro
Isabel Saez, M.
Gallardo Diaz, Enrique
Maria Gutierrez, Ana
Rodriguez-Antona, Cristina
机构：
[1] Fdn Hosp Madrid, Madrid, Spain
[2] Spanish Camcer Res Ctr, Madrid, Spain
[3] Complejo Hosp Navarra, Pamplona, Spain
[4] Hosp 12 Octubre, Madrid, Spain
[5] Hosp Univ Cent Asturias, Oviedo, Spain
[6] Fdn Inst Valenciano Oncol, Valencia, Spain
[7] Hosp Univ Clin San Carlos, Madrid, Spain
[8] Hosp Univ HM Sanchinarro, Madrid, Spain
[9] Hosp Univ Ramon y Cajal, Madrid, Spain
[10] Son Espases Univ Hosp, Palma De Mallorca, Spain
[11] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[12] Spanish Natl Canc Res Ctr, Madrid, Spain
[13] Hosp Univ Fdn Alcorcon, Alcorcon, Spain
[14] Hosp Althaia, Manresa, Spain
[15] Hosp Univ Fuenlabrada, Fuenlabrada, Spain
[16] Clara Campal Comprehens Canc Ctr CIOCC, Madrid, Spain
[17] Hosp Univ Virgen de la Victoria & Reg Malaga, CNIO IBIMA Genitourinary Canc Res Unit, CRIS Canc Fdn Prostate Canc Res Grp, Inst Biomed Res Malaga, Malaga, Spain
[18] Univ Autonoma Barcelona, Parc Tauli Sabadell Hosp Univ, Inst Invest Innovacio Parc Tauli, Dept Oncol, Sabadell, Spain
[19] Hosp Puerta Sur, Mostoles, Spain
[20] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4559
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Khalil, Lana
    Kang, Sandra
    McCook-Veal, Ashley
    Draper, Amber
    Diab, Maria
    Shaib, Walid Labib
    Alese, Olatunji B.
    El-Rayes, Bassel F.
    Akce, Mehmet
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors
    Fiorini, Claudia
    Massari, Francesco
    Pedron, Serena
    Sanavio, Sara
    Ciccarese, Chiara
    Porcaro, Antonio Benito
    Artibani, Walter
    Bertoldo, Francesco
    Zampini, Claudia
    Sava, Teodoro
    Ficial, Miriam
    Calio, Anna
    Chilosi, Marco
    D'Amuri, Alessandro
    Sanguedolce, Francesca
    Tortora, Giampaolo
    Scarpa, Aldo
    Delahunt, Brett
    Porta, Camillo
    Martignoni, Guido
    Brunelli, Matteo
    AMERICAN JOURNAL OF CANCER RESEARCH, 2014, 4 (06): : 907 - 915
  • [33] Retrospective analysis of ovarian cancer patients treated with PARP inhibitors.
    Liang, Connie
    Leung, Ashley
    Lee, Chung-Shien
    Hernandez, Jennifer
    Cheng, Kit
    Stefanov, Dimitre C.
    John, Veena S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC)
    Urun, Yuksel
    Gray, Kathryn P.
    Signoretti, Sabina
    McDermott, David F.
    Atkins, Michael B.
    Lampron, Megan E.
    Freedman, Matthew
    Choueiri, Toni K.
    Pomerantz, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] DNA methylation profiling in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
    Starzer, Angelika Martina
    Heller, Gerwin
    Tomasich, Erwin
    Feldmann, Katharina
    Hatziioannou, Teresa
    Traint, Stefan
    Minichsdorfer, Christoph
    Schwarz-Nemec, Ursula
    Nackenhorst, Maja
    Muellauer, Leonhard
    Preusser, Matthias
    Berghoff, Anna Sophie
    Fuereder, Thorsten
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Difference in Adverse Events of mTOR Inhibitors, Everolinus and Temsirolimus, in Metastatic Renal Cell Carcinoma Patients
    Nozawa, M.
    Shimizu, N.
    Yamamoto, Y.
    Minami, T.
    Hayashi, T.
    Yoshimura, K.
    Ishii, T.
    Uemura, H.
    UROLOGY, 2012, 80 (03) : S94 - S94
  • [37] Prognostic factors of the therapeutic efficacy of mTOR and VEGFR inhibitors in patients with metastatic renal cell carcinoma
    Voroshilova, E. A.
    Apanovich, N. V.
    Nosov, D. A.
    Karpukhin, A. V.
    Sokolova, I. N.
    Fedyanin, M. Yu.
    ONKOUROLOGIYA, 2015, 11 (04): : 34 - 41
  • [38] The Prognostic Value of Systemic Inflammatory Markers in Advanced Renal Cell Carcinoma Patients Treated With Molecular Targeted Therapies
    Ueda, Kosuke
    Ogasawara, Naoyuki
    Yonekura, Satoru
    Matsunaga, Yoshihiro
    Hoshino, Ryuji
    Kurose, Hirofumi
    Chikui, Katsuaki
    Uemura, Keiichiro
    Nakiri, Makoto
    Nishihara, Kiyoaki
    Matsuo, Mitsunori
    Suekane, Shigetaka
    Igawa, Tsukasa
    ANTICANCER RESEARCH, 2020, 40 (03) : 1739 - 1745
  • [39] PROGNOSTIC IMPACT OF CIRCULATING TUMOR DNA DYNAMICS IN ADVANCED RENAL CELL CARCINOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
    Koh, Yoko
    Uemura, Motohide
    Yamamichi, Gaku
    Yumiba, Satoru
    Tomiyama, Eisuke
    Matsushita, Makoto
    Nakano, Kosuke
    Hayashi, Yujiro
    Kato, Taigo
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Imamura, Ryoichi
    Nonomura, Norio
    JOURNAL OF UROLOGY, 2021, 206 : E705 - E706
  • [40] Association of race with clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs)
    Choi, Yujin
    Yildirim, Ahmet
    Wei, Mengting
    Liu, Yuan
    Goswamy, Rohit Vivek
    Brown, Jacqueline T.
    Nazha, Bassel
    Martini, Dylan J.
    Hartman, Caitlin
    McClintock, Greta Russler
    Zhuang, Tony
    Kissick, Haydn
    Harris, Wayne B.
    Carthon, Bradley Curtis
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345